MAR Elements and Transposons for Improved Transgene Integration and Expression by Ley, Deborah et al.
MAR Elements and Transposons for Improved Transgene
Integration and Expression
De´borah Ley1, Niamh Harraghy1, Vale´rie Le Fourn2, Solenne Bire3, Pierre-Alain Girod2,
Alexandre Regamey2, Florence Rouleux-Bonnin4, Yves Bigot3, Nicolas Mermod1*
1 Institute of Biotechnology, University of Lausanne, and Center for Biotechnology UNIL-EPFL, Lausanne, Switzerland, 2 Selexis SA, Geneva, Switzerland, 3 PRC, UMR INRA-
CNRS 7247, Centre INRA Val de Loire, Nouzilly, France, 4GICC, UMR CNRS 7292, UFR de Me´decine, Tours, France
Abstract
Reliable and long-term expression of transgenes remain significant challenges for gene therapy and biotechnology
applications, especially when antibiotic selection procedures are not applicable. In this context, transposons represent
attractive gene transfer vectors because of their ability to promote efficient genomic integration in a variety of mammalian
cell types. However, expression from genome-integrating vectors may be inhibited by variable gene transcription and/or
silencing events. In this study, we assessed whether inclusion of two epigenetic control elements, the human Matrix
Attachment Region (MAR) 1–68 and X-29, in a piggyBac transposon vector, may lead to more reliable and efficient
expression in CHO cells. We found that addition of the MAR 1–68 at the center of the transposon did not interfere with
transposition frequency, and transgene expressing cells could be readily detected from the total cell population without
antibiotic selection. Inclusion of the MAR led to higher transgene expression per integrated copy, and reliable expression
could be obtained from as few as 2–4 genomic copies of the MAR-containing transposon vector. The MAR X-29-containing
transposons was found to mediate elevated expression of therapeutic proteins in polyclonal or monoclonal CHO cell
populations using a transposable vector devoid of selection gene. Overall, we conclude that MAR and transposable vectors
can be used to improve transgene expression from few genomic transposition events, which may be useful when
expression from a low number of integrated transgene copies must be obtained and/or when antibiotic selection cannot be
applied.
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Introduction
Efficient gene transfer and expression for functional studies,
protein production or gene and cell therapies usually requires
reliable DNA delivery and transcription into target cells. Gene
transfer methods based on viral and non-viral vectors have been
developed to maximize gene delivery and expression, but an
expression system combining high levels of reliability, efficacy and
safety is currently lacking. For instance, non-viral vectors are
associated with a reduced risk of insertional mutagenesis when
compared to e.g. retroviral vectors for gene or cell therapies, and
they are easier to produce [1]. However, they typically require
physical (e.g. electroporation) or chemical (e.g. cationic lipids)
DNA transfer methods that are not easily applied in vivo, and they
are less efficient than viral vectors when genomic integration of the
transgene is necessary.
Genome integration is usually a requisite for persistent
transgene expression in dividing cells. Integration can be mediated
by cellular activities when plasmid vectors are used. For instance,
stable transfection relies on the selection of rare cells having
integrated plasmid DNA into one or few genomic loci, as a result
of the action of cellular DNA repair and recombination enzymes
[2]. This leads to the integration of multi-copy plasmid con-
catemers, usually as head-to-tail arrays [3,4]. However, repetitive
transgene arrays are prone to unstable expression, especially when
gene amplification methods are applied, which can result in
variable transgene expression or silencing [5]. Thus, epigenetic
regulatory elements are often added to plasmid vectors to alleviate
such unfavorable effects, and very high levels of expression can
therefore be obtained from cultured cells lines in vitro [6].
Nevertheless, the integration of many transgene copies can
complicate the screening of cell lines producing recombinant
proteins for pharmaceutical use. Indeed, it is expected to increase
the probability of observing point mutations in one or few copies,
which are often difficult to detect during early cell line
characterization stages, and it has been associated to repeat-
induced silencing events [5–7].
Alternatively, DNA recombination enzymes such as transpo-
sases, viral integrases, or synthetic integrases may be expressed
transiently in target cells or introduced together with the
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transgene-bearing DNA to assist transgene integration. This
usually yields increased frequencies of transgene integrations when
compared to plasmid vectors. Among these are the proteins
mediating targeted genomic DNA cleavage, such as the mega-
nucleases and zinc finger nucleases that allow DNA integration in
particular genomic loci, in contrast to the more random
integration events mediated by viral integrases and transposases
[8]. However, targeted integration usually occurs in a subset of the
cells only, and it results in the integration of one or two transgene
copies at the most, which limits expression. Recombinases and
nucleases can also mediate non-specific DNA cleavage events and
chromosomal rearrangements [9], which limits their use to in vitro
cultured cells.
Among non-viral vectors, transposons are particularly attractive
because of their ability to integrate single copies of DNA sequences
with high frequency at multiple loci within the host genome [10].
Unlike viral vectors, some transposons were reported not to
integrate preferentially close to cellular genes, and they are thus
less likely to introduce deleterious mutations. Moreover, transpo-
sons are readily produced and handled, consisting of a transposon
donor plasmid containing the cargo DNA flanked by inverted
repeat sequences and of a transposase-expressing helper plasmid
or mRNA. Several transposon systems were developed to mobilize
DNA in a variety of cell lines without interfering with endogenous
transposon copies. For instance, the piggyBac (PB) transposon
originally isolated from the cabbage looper moth [11] efficiently
transposes cargo DNA into a variety of mammalian cells [12].
Epigenetic regulatory elements can be used to protect the
transgene from unwanted epigenetic effects when placed near the
transgene on plasmid vectors. For example, elements called matrix
attachment region (MARs) were proposed to increase transgene
genomic integration and transcription while preventing hetero-
chromatin silencing, as exemplified by the potent human MAR 1–
68 [2,13,14]. They can also act as insulators and thereby prevent
the activation of neighboring cellular genes [15]. MAR elements
have thus been used to mediate high and sustained expression in
the context of plasmid or viral vectors [16]. However, whether
these favorable properties of the MAR elements may be combined
to those of transposable vectors remains essentially untested, and
their potential effects on transposition efficacy and/or transgene
expression when placed within a transposon remain unknown.
Here, we evaluated the use of a piggyBac transposon containing
human MARs in CHO cells. We show that MARs may be
included in transposon vectors to mediate efficient and sustained
expression from a few transgene copies, using cell populations
generated without an antibiotic selection procedure.
Results
Effect of MAR Inclusion on Transposition Efficiency
Transposition efficiency varies significantly depending on the
transposon system and cell type. Therefore, we first determined
optimal transfection conditions for our model CHO cells.
Different quantities and ratios of plasmid bearing the puromycin
resistance-carrying transposon and of the PB transposase expres-
sion vector were co-transfected into cultured cells, and the
occurrence of antibiotic-resistant colonies were scored (Figure
S1A and S1B), as performed in earlier studies [17,18]. The
frequency of puromycin-resistant colonies was increased up to 5-
fold in the presence of the transposase, when compared to
spontaneous genomic integration of the plasmids upon co-
transfections with a PB-devoid control plasmid (Figure S1C and
data not shown). This indicated that the PB transposase was very
likely functional in CHO cells.
As antibiotic resistance does not necessarily reflect efficient
transgene expression, we next used the green fluorescent protein
(GFP) expressed from a strong GAPDH cellular promoter
derivative as an indicator. To test whether adding a MAR
element to the PB transposon may affect transposition efficiency
and transgene expression, and to assess whether the location of
the MAR in the construct had any influence on these effects,
we designed a series of transposon donor constructs containing
the GFP and puromycin resistance (Puro) gene, in which the
MAR 1–68 or a control neutral spacer DNA sequence were
inserted at different positions in the plasmid (Figure 1). The
parental Puro-GFP transposon plasmid without an insert was
used as a control of transposition, to distinguish the impact of
increased transposon size relative to effect of the MAR or
spacer sequence addition.
We first estimated the transposition efficiency of the various
transposon constructs by assessing the percentage of GFP-
expressing cells after transfection and three weeks of cultivation
without antibiotic selection, so as to dilute away and eliminate
non-integrated and thus non-replicating episomal plasmids. In
parallel, we also assessed transposition efficiency by counting
puromycin-resistant colonies as before. When using the parental
Puro-GFP transposon vector, cytofluorometry analysis indicated
that approximately 3% of the cells stably expressed GFP when the
transposase was expressed, whereas less than 0.2% retained
detectable expression from spontaneous genomic integration
resulting from cellular recombination activities (Figure 2A and
Figure S2). The MAR or spacer sequence did not alter the
occurrence of cells stably expressing GFP from transposition
events when included downstream of the puromycin resistance
coding sequence but upstream of the promoter and enhancer
driving GFP expression (Figure 2A, Puro-MAR-GFP vs Puro-
spacer-GFP constructs, filled columns). However, the MAR
significantly inhibited transposition when placed at the transposon
extremity next to one of the inverted terminal repeats (ITR), but
not when it was placed on the external side of the ITR, just outside
of the transposed sequences (Figure 2A, Puro-GFP-MAR vs. Puro-
GFP-itr-MAR), suggesting topological constraints to the trans-
position mechanism.
Antibiotic selection yielded a lower apparent transposition
frequency from the parental Puro-GFP construct (3% vs. 0.6%,
Figure 2A and 2B), implying that transposition does not always
allow expression of the puromycin resistance gene at levels that are
sufficiently high to mediate cell survival, while detection of low
GFP expression levels can be detected by cytofluorometry. Apart
from this difference, similar conclusions were reached, i.e.
a centrally located MAR did not alter significantly the occurrence
of transposition events, while MAR inclusion at the edge of the
transposon inhibited transposition when compared to the control
containing a neutral spacer sequence. Inclusion of the MAR either
upstream or downstream of the GFP coding sequence also
increased the occurrence of antibiotic resistant colonies by
spontaneous plasmid integration in the absence of the transposase,
as observed in previous studies (Figure 2B, open columns) [13].
However, this effect was more pronounced when scoring antibiotic
resistance than GFP fluorescence, indicating that it may be
attributed in part to the occurrence and selection of a minority of
highly-expressing and antibiotic-resistant cells obtained in pres-
ence of the MAR element.
Effect of MAR Inclusion on Expression from Transposed
Genes
Apart from transposition efficiency, another aspect of transpos-
able vectors is the level of expression they allow. This was analyzed
Transposon and MAR-Mediated Expression
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by probing the GFP fluorescence levels of the CHO cells cultured
for 3 weeks with or without selection for puromycin resistance, and
with or without transposase expression, taking into account the
fluorescence of GFP-positive cells only, so that variable trans-
position or genomic integration frequencies did not influence
expression values. In the absence of the transposase and without
puromycin selection, the MAR significantly increased expression
when placed upstream of the GFP transgene (Figure 3A), as
expected from its known effect to improve transcription efficiency
and to decrease silencing [19]. However, inclusion of MAR 1–68
just downstream of the GFP gene had little effect on expression,
while placing the MAR further downstream restored some
activation of GFP expression. This indicated that the relative
positions and/or distance of the MAR and transgene expression
elements can modulate the activation effect.
In the presence of the transposase, the highest level of GFP
expression from unselected cells was observed when the MAR
was centrally located, but not when the MAR was placed
downstream of the GFP coding sequence, nor when inserted
outside of the transposed sequence as expected (Figure 3A). In
the presence of puromycin selection, the MAR-mediated
activation was reduced, either with or without the transposase,
while the GFP expression averages were increased by one order
of magnitude (Figure 3B). This confirmed that puromycin
selection yielded only the minority of the cells that display the
highest expression levels, as proposed above from the quanti-
tation of transposition events. It further indicated that the
transposable vectors containing a centrally located MAR yielded
similar expression levels when compared to their plasmid
counterpart transfected without the transposase.
Effect of MAR Inclusion on the Copy Number of
Integrated Transposon
Higher GFP fluorescence levels may result from an increased
transcription of the transgenes and/or by the integration of more
transgene copies [2,19]. This was assessed by quantifying the
number of genome-integrated transgene copies resulting from the
various types of vectors. Total genomic DNA was isolated from
pooled populations of cells, either after cytofluorometric sorting of
fluorescent cells from unselected populations or after selection for
puromycin resistance. The transgene copy number was de-
termined by quantitative polymerase chain reaction (qPCR)
analysis of the GFP coding sequence relative to the cellular b2-
microglobulin (B2M) gene. In the absence of antibiotic selection,
the average number of transgenes integrated by either the
transposase or by cellular recombination enzymes were similar,
around 1–6 copies per genome, and they were not significantly
affected by the MAR or control sequence (Figure S3A). However,
the lowest copy number was obtained when the MAR was
included at the transposon edge, supporting our earlier conclusion
that it decreases transposition at this location. After selection for
highly expressing cells with puromycin, the number of transposed
transgenes was in a similar 2–7 copy range (Figure S3B). However,
the number of transgenes copies integrated in the absence of the
transposase was generally significantly higher, ranging from 6 to
14 copies. This can be readily explained by the fact that
spontaneous integration usually results in the integration of
concatemers of multiple plasmid copies at a single genomic locus
(Figure S2), and that higher transgene copy numbers should lead
to higher expression levels when cells subjected to silencing effects
have been removed by antibiotic selection. Taken together with
the prior conclusion that antibiotic selection preferentially yields
highly expressing cells, this also indicated that spontaneous
Figure 1. Overview of the GFP expression constructs used in this study. The piggyBac inverted terminal repeats (ITR), the transposase
coding sequence (PB), the bacterial origin of replication (Ori) and the ampicillin selection gene (Amp) schematically depict the plasmids used in this
study. The puromycin resistance (Puro) and reporter green fluorescent protein (GFP) genes are illustrated by yellow and green arrows and the spacer
or MAR 1–68 sequences are shown by white or blue boxes on the transposon donor plasmid derivatives.
doi:10.1371/journal.pone.0062784.g001
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plasmid integration results in a more variable number of transgene
copies than transposable vectors.
We then normalized GFP expression to the gene copy number
to assess the intrinsic expression potential of the vectors,
independently from their propensity to integrate in the genome.
Overall, lower expression per transgene copy was obtained from
unselected cells, or from antibiotic-selected cells transfected
without transposase or centrally-located MAR, indicating that
transgene expression is influenced both by the inclusion of the
epigenetic regulatory element and by the mode of transgene
integration (Figure 4). Expression per gene copy was generally
increased by the transposase, when assessed from various vectors
and combination of elements, and this was observed with or
without antibiotic selection. The highest levels of expression per
transgene copy were obtained after antibiotic selection from the
cells generated with the transposon vector containing the MAR
element centrally located and in presence of the transposase.
Inclusion of the MAR immediately downstream of the GFP coding
sequence did not increase transgene expression significantly, as
noted earlier for the absolute levels of expression.
Finally, we assessed whether the favorable effect of MAR 1–68
on expression may be specific to the strong human GAPDH
promoter used here, or whether it would also occur with other
promoters. Thus we replaced the human GAPDH promoter
driving GFP expression by the weaker simian virus 40 (SV40) early
promoter. Use of the weaker promoter yielded comparable
numbers of GFP-positive cells and of integrated transgenes,
indicating that the transposition efficiency is not altered by
transgene expression (Figure S4A and S4B vs. Figure 2A and S3B).
However, the absolute levels of expression were lower with the
SV40 promoter (Figure S4C vs. 3B). In addition, expression
normalized to the transposon copy number was decreased by 4.6-
fold by the use of the SV40 promoter in the absence of the MAR,
and by 3.1-fold with MAR 1–68 (Figure S4D vs. 4B). This
indicated that the MAR could partially, but not fully prevent the
decrease of expression resulting from the use of a weaker
promoter, even in presence of the transposase. Overall, we
concluded that a few integrated copies are sufficient to obtain high
transgene expression from transposons, and that the highest
expression per transgene is obtained when MAR 1–68 is placed
upstream of the strong promoter.
Expression of Therapeutic Proteins from Transposon
Vectors Devoid of Selectable Gene
We next wished to determine whether MAR-containing
transposons may be used to express therapeutic proteins using
the CHO-M cell line grown in suspension culture [2], and whether
Figure 2. Effect of MAR and transposon size on transposition efficiency. CHO cells were co-transfected with 300 ng of Puro-GFP, Puro-MAR-
GFP, Puro-GFP-MAR or Puro-GFP-ITR-MAR plasmids, or with their respective control plasmids containing the spacer, with 300 ng PB transposase
(filled boxes) or control plasmids (open boxes). Grey arrows on the plasmid schematic representations indicate the position of the MAR or spacer
DNA, while black arrows depict PB’s ITR. (A) Cells were cultured for 3 weeks after transfection without selection pressure and the percentage of GFP-
expressing cells was quantified by cytofluorometry. (B) Puromycin-resistant colonies from 50 000 transfected cells were counted after 2 weeks with
puromycin selection. The percentage of cells leading to puromycin resistant colonies was determined. Values represent the means 6 SEM (n= 3).
*P,0.05, **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0062784.g002
Transposon and MAR-Mediated Expression
PLOS ONE | www.plosone.org 4 April 2013 | Volume 8 | Issue 4 | e62784
antibiotic selection may be dispensable. As cells growing in
suspension are not efficiently transfected by lipofection agents, we
first assessed CHO-M electroporation with the piggyBac vectors
containing MAR 1–68. Electroporation increased the frequency of
GFP expressing cells up to approximately 15% of the total cell
population when using the vector with the centrally located MAR
1–68, and expression was stably maintained for over 4 weeks of
culture without selection (Figure S5A). However, the presence of
this MAR at the edge of the transposon decreased transposition
efficiency, as observed earlier using cationic lipid-based gene
transfer. The antibiotic selection gene was removed from this
vector, and MAR 1–68 was replaced by another potent human
element, MAR X-29 [13]. Inclusion of the MAR X-29 at this
position restored a high proportion of GFP positive cells (Figure
S5A).
CHO-M cells were electroporated once or twice with the single
transgene MAR X-29-containing transposable vector, using
a multiple gene transfer procedure [2], and the total cell
populations were grown without selection for three weeks before
cytofluorometry analysis. A higher proportion of fluorescent cells
was recorded from two consecutive transfections performed in the
presence of the transposase as compared to transfections
performed without the transposase vector (Figure S5B). Electro-
poration yielded 30% and 45% of the cells stably expressing GFP
upon one or two successive transposon vector electroporations
respectively, which compares favorably to the 2–4% of positive
cells obtained from the lipofection of adherent cells (Figure 5A vs.
2A). Overall, this indicated that the transposition efficiency was
much higher after electroporation than with chemical transfection,
possibly because a higher proportion of cells take-up and
transiently express the transferred DNA when performing multiple
electroporation procedures. However, transgene expression levels
were similar, as the mean fluorescence levels of GFP-positive
electroporated cells were comparable to those obtained after
chemical transfection of the transposable vector (Figure 5B vs. 3A).
Expression cassettes encoding the heavy or light chains of three
therapeutic immunoglobulins (Bevacizumab, Adalimumab and
Rituximab) were inserted upstream of the MAR X-29 into the
transposable vector instead of the puromycin resistance and GFP
coding sequences. The resulting constructs were electroporated
thrice with the piggyBac transposase vector into CHO-M cells.
After three weeks of culture without selection, secretion of the
three antibodies was quantified from the cell culture supernatants.
Titers ranging from 1 to 8 mg/ml of Bevacizumab, Adalimumab
and Rituximab were obtained in several transfection experiments,
indicating that significant expression of these antibodies may be
obtained when assessing the culture supernatants of unselected
polyclonal cell populations (Figure 5C). These levels were further
increased to 23–55 mg/ml by sorting the expressing cells using
streptavidin-coated magnetic microbeads, so as to capture the cells
that transiently display the secreted immunoglobulins at their
surface [20]. This indicated that polyclonal cell populations may
be sorted to display and express therapeutic proteins in amounts
allowing analytical or functional studies, at levels similar to those
Figure 3. Effect of MAR on transgene expression levels. The average GFP fluorescence of the cells as described in the legend of Figure 2 was
quantified by cytofluorometric analysis, either after 3 weeks of culture without selection following transfection (A), or after 2 weeks under puromycin
selection (B). Values represent the means 6 SEM (n = 3). *P,0.05, **P,0.01, ***P,0.001. RLU : relative light unit.
doi:10.1371/journal.pone.0062784.g003
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PLOS ONE | www.plosone.org 5 April 2013 | Volume 8 | Issue 4 | e62784
previously obtained from transposable vectors after antibiotic
selection [21].
We next assessed whether highly expressing cell clones may
be obtained from the non-sorted and non-selected polyclonal
populations using an imaging device for cell colony productivity.
Two colonies displaying favorable size, indicative of fast cell
growth, and high immunoglubulin secretion were picked from
each of the three immunoglobulin-expressing cell populations.
Immunoglobulin secretion by the 6 cell clones was assessed
using small scale cell suspension cultures in spin tube
bioreactors. The immunoglobulin-expressing clones produced
antibody titers ranging between 0.55 to 1.2 g/L over the 9-day
fed-batch cultures (Figure 5D), while reaching high cell densities
and maintaining elevated viability (Figure S6). This indicated
that transposable vectors can yield cell clones displaying the
high titers, cell viability and cell density needed to produce
proteins for therapeutic use.
We next assessed whether transposon vectors may also be
used for the metabolic engineering of CHO cells to achieve
improved secretion of therapeutic proteins. We have recently
shown that the expression of difficult-to-express immunoglobu-
lins like the Infliximab antibody can be increased significantly
by the expression of proteins of the secretion pathway, such as
the signal peptide recognition proteins SRP9, SRP14, SRP54,
the SRPRalpha and SRPRbeta components of the SRP
complex receptor (SR), and/or the Translocon subunits [22].
CHO-M cells stably expressing the Infliximab antibody were
thus co-transfected either with a regular plasmid expression
vector and with a neomycin selection plasmid, or with the
transposase expression plasmid and transposable vectors expres-
sing similar combinations of secretion proteins. Cells transfected
with plasmid vectors were selected for spontaneous transgene
integration into their genome by neomycin selection, whereas
cells transfected with the transposable vectors were grown
without selection in parallel. Cultures of these polyclonal
populations were then assessed for specific antibody secretion
per day and per cell. Immunoglobulin expression was found to
be slightly improved, up to 1.5-fold relative to the control cells
expressing Infliximab only, upon the expression of secretion
proteins from plasmid vectors (Figure 6). However, higher
secretion of the therapeutic protein was obtained from trans-
posable vectors, with yields that were increased by more than
two-fold upon the expression of several combinations of
components of the protein secretion pathway. Thus, we
concluded overall that transposable vectors can be used to
increase the expression of recombinant proteins, either directly
by bearing the therapeutic protein coding sequences, or
indirectly, by allowing the expression of cellular proteins that
improve the secretion of the therapeutic protein. Furthermore,
the use of transposable vectors allowed easy integration of
numerous transgenes into the cell’s genome, obviating the need
for multiple antibiotic selection genes.
Figure 4. Effect of MAR on transposon copy number. The copy number of integrated GFP was determined using qPCR as described in
supplementary. Fig S4, using unselected puromycin-resistant cells generated as described in the legends of Figure 2. The mean GFP fluorescence was
divided by the number of integrated GFP transgene copies, to estimate the average expression per integrated GFP copy in unselected (A) and
puromycin-resistant (B) CHO cells. Values represent the means 6 SEM (n= 3). *P,0.05.
doi:10.1371/journal.pone.0062784.g004
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Discussion
So far, most studies involving transposable vectors have relied
on antibiotic resistance-based assays, which has not allowed a clear
and quantitative disentanglement of transgene copy number-
linked effects from those elicited by variations of transgene
expression levels. In this study, we wished to evaluate the potential
benefit of adding an epigenetic regulator to a transposable vector
in conditions allowing the quantitative assessment of both
transposition efficiency and transgene expression. This study
shows that the human MAR 1–68 can be added at a central
position in the piggyBac transposon without decreasing trans-
position efficiency, while it’s insertion at the transposon edge may
interfere with the transposase function, both in terms of trans-
position efficiency, and, surprisingly, expression per transgene.
Inclusion of the MAR 1–68 at the edge of the transposon may
cause topological constraints that would hinder the joining of the
two ITR by the transposase, which would in turn reduce transgene
integration by the transposase. The decrease of expression per
transgene copy elicited by MAR 1–68 when inserted at the
transposon edge suggests that the transposons may have integrated
at genomic loci that are less favorable for expression. Thus, the
MAR 1–68 may have altered the mechanism by which the
transposase targets a genomic locus to integrate the transposon
sequence. Interestingly, this effect appears to be specific to MAR
1–68, as inclusion of human MAR X-29 at the edge of the
transposable sequence did not yield low transposition efficiency or
expression. While the cause of such MAR-dependent effects
remains unclear, this may result from the specific organization of
DNA bending-prone sequences as well as transcription factor
binding sites whose combinations and relative positions differ
when comparing distinct MAR elements [13].
Interestingly, the extent of the MAR-mediated activation of
transposed genes was reduced when compared to that of
spontaneous plasmid integration. Furthermore, the level of
expression, when normalized to transgene copies, was higher
from the transposons than those obtained from the spontaneous
Figure 5. Recombinant protein expression from electroporated CHO-M cell suspensions. (A) CHO-M cell were electroporated once or
twice with the MAR X-29-bearing GFP-expression transposon vector in the presence (+PB) or not (-PB) of the piggyBac transposase, as described in
Figure S5, and the percentage of stable GFP-expressing cells was assayed after 3 weeks of culture performed in the absence of selection. (B) Mean of
the GFP fluorescence of the GFP-positive cells. (C) cDNAs encoding immunoglobulin light and heavy chains of the Bevacizumab (Beva), Adalimumab
(Adal) and Rituximab (Ritu) antibody were introduced in MAR X29-containing transposon plasmids instead of GFP. The light and heavy chain
transposon constructs were electroporated three times at 12 days intervals with the piggyBac transposase expression vector in CHO-M cells, and the
levels of immunoglobulin secreted in the culture supernatants of polyclonal cell pools grown without selection was assayed (open bars).
Alternatively, the unselected polyclonal cell populations were sorted by panning cells displaying immunoglobulins at their surface using magnetic
micro-beads, and the levels of secreted immunoglobulins were assayed as for the unsorted populations (closed bars). (D) Alternatively,
immunoglobulin-expressing colonies were sorted from transfected cell populations using a colony-picking device, and two clones expressing each of
the three immunoglobulins were grown in fed-batch cultures in spin-tube bioreactors. The levels of secreted immunoglobulins were determined as
for panel (C).
doi:10.1371/journal.pone.0062784.g005
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integration of the plasmids in the absence of the transposase. This
effect was observed irrespective of the size of the constructs, of the
presence of the MAR or of promoter strength. This would be
expected if transposition might often occur at genomic loci that are
relatively permissive for expression, for instance because open
chromatin structures may be more accessible to both the
transposase and transcription factors. In this respect, previous
studies have suggested that transposons may preferentially in-
tegrate within gene introns [23], at promoters [24], or at genomic
loci with lower propensity for silencing, although this has remained
a matter of debate (see [25] for a review). Alternatively, the co-
integration of many plasmid copies at the same genomic locus, as
elicited by spontaneous integration events, may lead to the
formation of heterochromatin and to the silencing of repetitive
sequences, which the MAR would oppose, whereas single-copy
transposon integration may be less prone to such chromatin-
mediated silencing. In addition, the integration of transposons at
multiple independent genomic loci makes it likely that at least one
copy landed into a favorable genomic environment and is
expressed, whereas plasmid integration was found to occur
predominantly at just one genomic locus [13].
Further work may be required to determine why expression
from plasmid vectors is more dependent on the MAR than
transposon vectors. Nevertheless, our results indicate that the
highest expression levels per transgene were obtained from
a MAR-containing transposon when coupled to a strong pro-
moter, and that high expression levels can be obtained from a few
transposed transgene copies. Use of transposable vectors may be
advantageous for the production of proteins for pharmacological
use. For instance, fewer integrated transgene copies should be
advantageous if high productivities can nevertheless be obtained,
as documented in this study for three therapeutic antibodies,
because it should decrease the probability of point mutation
occurrence in one or in a subset of the transgenes, as elicited from
spontaneous mutagenic events. In addition, transposase-mediated
integration events may be less mutagenic than the DNA repair and
recombination mechanisms involved in spontaneous plasmid
integration, which can lead to incomplete or rearranged transgene
copies.
The high efficiency of genomic integration by the piggyBac
transposon should also be favorable when the amount of target
cells is limiting, for instance for the non-viral transfer of
therapeutic genes in primary stem cells to generate clonal
populations, with cell-based therapies or regenerative medicine
as perspectives. In this context, physiological expression levels
from a few transposed gene copies and the frequent occurrence of
transposition events, thus obviating the need for antibiotic
selection, should be of advantage, since the use of antibiotic
resistance genes and/or unreliable transgene expression may raise
safety concerns.
Finally, transposons should also be favorable for cellular
metabolic engineering, for instance to express secretion proteins
and/or when multiple rounds of gene introduction are required.
This is illustrated in this study by the expression of multiple
proteins of the cell’s secretory pathway, where the transfection of
multiple vectors and/or multiple successive transfection cycles may
Figure 6. Effect of the expression of secretion proteins from transposable and plasmid vectors on recombinant protein expression.
(A). Transposable or regular plasmid vectors were constructed to express secretion proteins SRP9, SRP14, SRP54, the SRP receptor a and b subunits
(SR), or the Translocon. Transposable vectors were co-transfected with the piggyBac transposase vector, whereas the non-transposable plasmid
vectors were transfected alone in a cell clone expressing the infliximab antibody [22]. After three weeks of culture without selection, the levels of
secreted infliximab antibody were assayed from cell culture supernatants. Data pertaining to the effect of transposable vectors are as in [22].
doi:10.1371/journal.pone.0062784.g006
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exhaust available antibiotic or other selection methods. Alterna-
tively, the ability to quickly express therapeutic proteins without
a need for antibiotic selection is of interest, for instance when
multiple therapeutic protein candidates must be expressed for
screening purposes, as significant amounts of proteins can be
obtained from unselected cell populations 2–3 weeks after
transfection. Overall, we thus conclude that MAR-containing
transposons will be useful additions to the currently available
arsenal of expression vectors.
Materials and Methods
Plasmids and DNA Vectors
The PB transposase expression vector pCS2+U5V5PBU3
contains the PB transposase coding sequence surrounded by the
59 and 39 untranslated terminal regions (UTR) of the Xenopus
laevis b-globin gene. This plasmid was constructed as follows: the
39 UTR 317 bp fragment from pBSSK/SB10 (kindly provided by
Dr S. Ivics) was inserted into pCS2+U5 (Invitrogen/Life
Technologies, Paisley, UK) to yield pCS2+U5U3. The PB
transposase coding sequence (2067 bp, GenBank accession num-
ber: EF587698) was synthesized by ATG:biosynthetic (Merzhau-
sen, Germany) and cloned in the pCS2+U5U3 backbone between
the two UTRs. The PB control vector corresponds to the
unmodified pCS2+U5 plasmid (Figure 1, left panel).
The different transposons vectors used in this study were
generated by introducing the PB 235 bp 39 and 310 bp 59 inverted
terminal repeats (ITRs), synthesized by ATG:biosynthetic (Merz-
hausen, Germany), into the pBluescript SK- plasmid (pBSK
ITR39-ITR59, Figure 1, right panel). The puromycin resistance
gene (PuroR), under the control of the SV40 promoter from pRc/
RSV plasmid (Invitrogen/Life Technologies), was then inserted
between the two ITRs. The MAR 1–68 and MAR X-29 elements,
the puromycin resistance and GFP genes used in this study were as
previously described [2,13,14]. The immunoglobulin expression
vectors and the SRP9, SRP14, SRP54, SRPRalpha, SRPRbeta,
SEC61A1, SEC61B and SEC61G coding sequences were as
described by Le Fourn et al. [22]. A DNA spacer of 3.6 kb
corresponding to the MAR 1–68 length was PCR-amplified from
the mouse utrophin cDNA and used as control without MAR. The
GFP, immunoglobulin or secretion proteins were expressed using
a eukaryotic expression cassette composed of a human CMV
enhancer and human GAPDH promoter upstream of the coding
sequence followed by a SV40 polyadenylation signal, the human
gastrin terminator and a SV40 enhancer [22]. For transposition
experiments from a weak promoter (Figure S6), the human
GAPDH promoter was replaced by the SV40 promoter.
Expression cassettes and/or MAR elements were inserted between
the ITR sequences or in the bacterial vector backbone as
illustrated in Figure 1 and in figure legends using standard cloning
methods. All plasmids, DNA vectors, and other renewable
resources, as represented in Figure 1, will be made freely available
for non-profit research use, unless specifically restricted by some
other party.
Cell Culture and Transfection Analysis
The CHO DG44 cell line [26] was cultivated in DMEM: F12
(Gibco) supplemented with Hypoxanthine/Thymidine (HT,
Gibco) and 10% fetal bovine serum (FBS, Gibco). Transfections
were performed using PEI (JetPRIME, Polyplus Transfection),
according to the manufacturer’s instructions. Cells were trans-
fected with various amounts of a supercoiled plasmid encoding the
PB transposase (ranging from 0 to 1500 ng) for titration
experiments or co-transfected with the optimal ratio of 300 ng
of PB transposase expression plasmid and 300 ng of transposon
donor plasmid. Supercoiled transposon-donor plasmids were used,
as it was shown that PB transposition from linear vector is
relatively inefficient when compared to circular transposon
plasmids [18]. Plasmids transfected as controls without the
transposase were also supercoiled, as the use of linearized plasmids
did not increase significantly the frequency of occurrence of
spontaneous integration (,2-fold, data not shown). Two days after
the transfection, cells were transferred to several Petri dishes
depending on the experiment. For analysis of unselected
transfected CHO cells, cells were replated without antibiotic
selection for 3 weeks and the percentage of fluorescent cells and
the fluorescence intensity of GFP positive cells were determined by
FACS analysis using a CyAn ADP flow cytometer (Beckman
Coulter). For gene copy number analysis of unselected cells, stable
GFP positive CHO cells were sorted using a FACSAriaII. For
antibiotic resistant colony-counting assays, 50,000 transfected cells
were seeded in 100 mm plates and selected with 5 mg/ml
puromycin for 2 weeks. Then, resistant colonies were fixed and
stained in 70% EtOH 0,7% Methylene Blue for 10 min, and
colonies .0.5 mm in diameter were counted. For GFP expression
studies, cells were selected for two weeks before GFP fluorescence
FACS analysis as described above.
CHO-M cells were maintained in suspension culture in
SFM4CHO Hyclone serum-free medium (ThermoScientific)
supplemented with L-glutamine (PAA, Austria) and HT supple-
ment (Gibco, Invitrogen life sciences) at 37uC, 5% CO2 in
humidified air. Transposon donor plasmids were transferred in
these cells by electroporation according to the manufacturer’s
recommendations (Neon devices, Invitrogen). Quantification of
immunoglobulin secretion was performed from batch cultures as
described previously [22]. Briefly, cell populations expressing
immunoglogulins were evaluated in batch cultivation into 50 ml
minibioreactor tubes (TPP, Switzerland) at 37uC in 5% CO2
humidified incubator for 7 days. Immunoglobulin concentrations
in cell culture supernatants were measured by sandwich ELISA.
qPCR Gene Copy Number Assays
Total DNA was isolated from CHO stable cell pools following
transposition assays using the DNeasy Tissue Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s protocol. The copy
number of genome-integrated transgenes was assessed using 6 ng
of genomic DNA by quantitative PCR using the SYBR Green-
Taq polymerase kit from Eurogentec Inc and ABI Prism 7700
PCR machine (Applied Biosystems). The GFP-Forward: ACAT-
TATGCCGGACAAAGCC and GFP-Reverse:
TTGTTTGGTAATGATCAGCAAGTTG primers were used
to quantify the GFP gene, while primers B2M-Forward:
ACCACTCTGAAGGAGCCCA and B2M-Reverse:
GGAAGCTCTATCTGTGTCAA were used to amplify the
Beta-2 microglobulin gene. For the amplicon generated by the
B2M primers, one hit was found per CHO haploid genome after
alignment to our CHO genome assembly using NCBI BLAST
software. As CHO are near-diploid cells [27], we estimated that
B2M is present at 2 copies per genome. The ratios of the GFP
target gene copy number were calculated relative to that of the
B2M reference gene, as described previously [28].
Sorting and Assay of Immunoglobulin-expressing Cells
To magnetically sort IgG-expressing cells, transfected CHO-M
cells were seeded at a cell density of 36105 cells per ml in
SFM4CHO medium (Thermo Scientific) supplemented with
8 mM L-glutamine and 16 HT supplement (both from Gibco),
referred to as Complete Medium. After 4 days in culture, 26106
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cells were washed, re-suspended in PBS and incubated with
a biotinylated human IgG (KPL216-1006) at a final concentration
of 3 mg/ml, together with 30 ml pre-washed MyOne T1
streptavidin-coated Dynabeads (Invitrogen), on a rotary wheel
for 30 minutes at room temperature. The cell and bead mix was
then placed on a magnet to separate labeled cells from non-labeled
cells. The beads were washed 4 times with a phosphate buffer
saline (PBS) solution. After the final PBS wash, the beads and cells
were re-suspended in 500 ml pre-warmed Complete Medium,
transferred to a 24 well plate and incubated at 37uC with 5% CO2.
After 24 h the magnetically-sorted polyclonal cells were separated
from the beads and incubation was continued until the cells were
of a sufficient density for expansion in 50 mL TPP spin tube
bioreactors (Techno Plastic Products AG, Switzerland).
Alternatively, two clones were isolated from non-sorted and
non-selected populations expressing each of the three IgGs using
a ClonePix device. Briefly, semi-solid media was used to
immobilize single cells, and colonies secreting high amounts of
IgG were picked ten days post-embedding. These cell lines were
passaged every 3–4 days in spin tube bioreactors at a density of
36105 cells/ml in a peptone-containing growth medium (Hyclone
SFM4CHO supplemented with 8 mM glutamine) in a humidified
incubator maintained at 37uC and 5% CO2, with orbital shaking
at 180 rpm.
IgG titers were determined from cells seeded at a cell density of
16105 cells per ml and grown for 6 days in 5 ml of Complete
Medium in 50 ml Spin tube bioreactors when assessing polyclonal
cell populations. Alternatively, shake flask cultures of clonal
populations were inoculated at a density of 36105 cells/ml into
SFM4CHO media to initiate the fed batch production process.
Fed batch production assays were performed with 25 ml of culture
volume in 125 ml shake flasks or 5 ml in 50 ml TPP culture tubes
in humidified incubators maintained at 37uC and 5% CO2 with
shaking at 150 rpm (125 ml shake flask and spin tubes). The
production was carried out for ten days by feeding 16%, of the
initial culture volume of chemically defined concentrated feed
(Hyclone, Cell Boost 5, 52 g/l) on days zero, three and six to eight.
No glutamine and glucose feeding was applied during the culture
run. The viability and viable cell density (VCD) of the culture was
measured daily using a GUAVA machine (Millipore). A double
sandwich ELISA assay was used to determine MAb concentrations
secreted into the culture media.
Supporting Information
Figure S1 Optimization of piggyBac transfection condi-
tions in CHO cells. PB transposition activity was measured
under fixed amount of the puromycin resistance gene bearing
transposon plasmid (300 ng) co-transfected with increased amount
of transposase plasmid. (A) Puromycin resistant colonies were
stained after 2 weeks of selection. (B) Fold increase in colony
number induced by the PB transposase. Values represent the
means 6 SD (n= 2).
(TIFF)
Figure S2 Models of transgene integration from trans-
fected plasmids. (A) Model of multi-copy plasmid chromosomal
integration resulting from classical stable transfection methods,
resulting in a preferential head-to-tail transgene organization [3,4].
(B) Mode of excision of a transposon (flanked by ITR sequences)
from a donor plasmid, and single-copy integration at one or
several loci in the host genome by the transposase.
(TIFF)
Figure S3 Effect of MAR and transposase upon in-
tegrated transgene copy number. The number of integrated
GFP transgene copies was determined using qPCR, and values
were normalized relative to the cellular B2M gene, using genomic
DNA isolated from unselected CHO cells (A), or puromycin-
resistant cells (B) generated as described in the legends to Figs 2
and 3. Values represent the means 6 SEM (n= 3). *P,0,05.
(TIF)
Figure S4 Effect of MAR 1–68 on transposition efficacy
and transgene expression from a weak promoter. CHO
cells were transfected as described in the legend to Figure 2 using
transposon donor constructs containing a centrally located spacer
or MAR sequence, as indicated, except that the GAPDH
promoter driving GFP expression was replaced by the SV40
promoter. The percentage of GFP positive cells (A) was de-
termined from unselected cells as for Figure 2A, whereas the GFP
transgene copy number normalized to the cellular betamicroglo-
bulin gene (B), the mean cellular fluorescence (C), and the GFP
fluorescence normalized to the GFP transgene copy number (D),
were determined from puromycin-selected cells, as described for
Figure S3, 3B and 4B, respectively. Values represent the means 6
SEM (n= 3). *P,0,05, **P,0.01, ***P,0.001.
(TIF)
Figure S5 Assay of single transgene MAR-bearing trans-
posable vectors. (A) CHO-M cells were electroporated with the
depicted transposon donor constructs containing or not human
MAR 1–68 or X-29 together with the piggyBac transposase
expression vector. The percentage of GFP positive cells was
determined from the total cell population maintained in
suspension culture for 12 or 33 mean population doubling time.
(B) Densitometric profiles of CHO-M electroporated with the
GFP-MARX-29 transposon donor with (+PB) or without (-PB) the
piggyBac transposase expression vector. Cell fluorescence was
assayed after single or double transfections followed by 3 weeks of
cell culture performed in the absence of selection. The horizontal
bar indicates the sectors used to quantify expressing from non-
expressing cells.
(TIFF)
Figure S6 Culture growth of cell clones producing
therapeutic antibodies from transposable vectors. The
viable cell densities (A) and the cell viability (B) are shown for the
tube spin bioreactor runs displayed in Figure 5D for the indicated
cell clones (labeled A or B) expressing the Bevacizumab (Beva),
Adalimumab (Adal) or Rituximab (Ritu) antibody.
(TIF)
Author Contributions
Conceived and designed the experiments: NM PAG YB FRB. Performed
the experiments: DL VLF NH SB AR. Analyzed the data: DL VLF NH SB
AR NM PAG YB FRB. Contributed reagents/materials/analysis tools: SB
YB FRB VLF AR PAG. Wrote the paper: DL NH NM.
References
1. Gao X, Kim KS, Liu D (2007) Nonviral gene delivery: what we know and what
is next. AAPS J 9: E92–104.
2. Grandjean M, Girod PA, Calabrese D, Kostyrko K, Wicht M, et al. (2011)
High-level transgene expression by homologous recombination-mediated gene
transfer. Nucleic Acids Res 39: e104.
Transposon and MAR-Mediated Expression
PLOS ONE | www.plosone.org 10 April 2013 | Volume 8 | Issue 4 | e62784
3. Folger KR, Wong EA, Wahl G, Capecchi MR (1982) Patterns of integration of
DNA microinjected into cultured mammalian cells: evidence for homologous
recombination between injected plasmid DNA molecules. Mol Cell Biol 2:
1372–1387.
4. Hoglund M, Siden T, Rohme D (1992) Different pathways for chromosomal
integration of transfected circular pSVneo plasmids in normal and established
rodent cells. Gene 116: 215–222.
5. McBurney MW, Mai T, Yang X, Jardine K (2002) Evidence for repeat-induced
gene silencing in cultured Mammalian cells: inactivation of tandem repeats of
transfected genes. Exp Cell Res 274: 1–8.
6. Kwaks TH, Otte AP (2006) Employing epigenetics to augment the expression of
therapeutic proteins in mammalian cells. Trends Biotechnol 24: 137–142.
7. Rhounim L, Rossignol JL, Faugeron G (1992) Epimutation of repeated genes in
Ascobolus immersus. EMBO J 11: 4451–4457.
8. Silva G, Poirot L, Galetto R, Smith J, Montoya G, et al. (2011) Meganucleases
and other tools for targeted genome engineering: perspectives and challenges for
gene therapy. Curr Gene Ther 11: 11–27.
9. Loonstra A, Vooijs M, Beverloo HB, Allak BA, van Drunen E, et al. (2001)
Growth inhibition and DNA damage induced by Cre recombinase in
mammalian cells. Proc Natl Acad Sci U S A 98: 9209–9214.
10. Ivics Z, Li MA, Mates L, Boeke JD, Nagy A, et al. (2009) Transposon-mediated
genome manipulation in vertebrates. Nat Methods 6: 415–422.
11. Handler AM, McCombs SD, Fraser MJ, Saul SH (1998) The lepidopteran
transposon vector, piggyBac, mediates germ-line transformation in the
Mediterranean fruit fly. Proc Natl Acad Sci U S A 95: 7520–7525.
12. Belay E, Dastidar S, VandenDriessche T, Chuah MK (2011) Transposon-
mediated gene transfer into adult and induced pluripotent stem cells. Curr Gene
Ther 11: 406–413.
13. Girod PA, Nguyen DQ, Calabrese D, Puttini S, Grandjean M, et al. (2007)
Genome-wide prediction of matrix attachment regions that increase gene
expression in mammalian cells. Nat Methods 4: 747–753.
14. Hart CM, Laemmli UK (1998) Facilitation of chromatin dynamics by SARs.
Curr Opin Genet Dev 8: 519–525.
15. Gaussin A, Modlich U, Bauche C, Niederlander NJ, Schambach A, et al. (2012)
CTF/NF1 transcription factors act as potent genetic insulators for integrating
gene transfer vectors. Gene Ther 19: 15–24.
16. Harraghy N, Gaussin A, Mermod N (2008) Sustained transgene expression using
MAR elements. Curr Gene Ther 8: 353–366.
17. Grabundzija I, Irgang M, Mates L, Belay E, Matrai J, et al. (2010) Comparative
analysis of transposable element vector systems in human cells. Mol Ther 18:
1200–1209.
18. Nakanishi H, Higuchi Y, Kawakami S, Yamashita F, Hashida M (2011)
Comparison of piggyBac transposition efficiency between linear and circular
donor vectors in mammalian cells. J Biotechnol 154: 205–208.
19. Galbete JL, Buceta M, Mermod N (2009) MAR elements regulate the
probability of epigenetic switching between active and inactive gene expression.
Mol Biosyst 5: 143–150.
20. Brezinsky SC, Chiang GG, Szilvasi A, Mohan S, Shapiro RI, et al. (2003) A
simple method for enriching populations of transfected CHO cells for cells of
higher specific productivity. J Immunol Methods 277: 141–155.
21. Matasci M, Baldi L, Hacker DL, Wurm FM (2011) The PiggyBac transposon
enhances the frequency of CHO stable cell line generation and yields
recombinant lines with superior productivity and stability. Biotechnol Bioeng
108: 2141–2150.
22. Le Fourn V, Girod PA, Buceta M, Regamey A, Mermod N (2013) CHO cell
engineering to prevent polypeptide aggregation and improve therapeutic protein
secretion. Metab Eng, in press, DOI: 10.1016/j.ymben.2012.12.003.
23. Ding S, Wu X, Li G, Han M, Zhuang Y, et al. (2005) Efficient transposition of
the piggyBac (PB) transposon in mammalian cells and mice. Cell 122: 473–483.
24. Wilson MH, Coates CJ, George AL, Jr. (2007) PiggyBac transposon-mediated
gene transfer in human cells. Mol Ther 15: 139–145.
25. Meir YJ, Weirauch MT, Yang HS, Chung PC, Yu RK, et al. (2011) Genome-
wide target profiling of piggyBac and Tol2 in HEK 293: pros and cons for gene
discovery and gene therapy. BMC Biotechnol 11: 28.
26. Urlaub G, Kas E, Carothers AM, Chasin LA (1983) Deletion of the diploid
dihydrofolate reductase locus from cultured mammalian cells. Cell 33: 405–412.
27. Derouazi M, Martinet D, Besuchet Schmutz N, Flaction R, Wicht M, et al.
(2006) Genetic characterization of CHO production host DG44 and derivative
recombinant cell lines. Biochem Biophys Res Commun 340: 1069–1077.
28. Karlen Y, McNair A, Perseguers S, Mazza C, Mermod N (2007) Statistical
significance of quantitative PCR. BMC Bioinformatics 8: 131.
Transposon and MAR-Mediated Expression
PLOS ONE | www.plosone.org 11 April 2013 | Volume 8 | Issue 4 | e62784
